Xenon Pharmaceuticals (NASDAQ:XENE) was having a pretty quiet 2021. For most of the year, XENE stock traded between $15 and $20 with minimal volatility. However, that changed in a hurry early in ...

Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are thrilled to announce the launch of our XEN1101 Phase 3 program with the initiation of our X-TOLE2 clinical trial.